Current perspectives on the use of gene therapy for hypertension.
Systemic hypertension is a pathophysiological state that is manifested as high blood pressure and is a major risk factor for stroke, ischemic heart disease, peripheral vascular disease, and progressive renal damage. Pulmonary hypertension occurs in 3 distinct forms: primary pulmonary hypertension, pulmonary hypertension of the newborn, or secondary pulmonary hypertension attributable to a variety of lung and cardiovascular diseases. This review discusses the use of gene therapy in the control of systemic and pulmonary hypertension. Overexpression of vasodilator genes as well as antisense knockdown of vasoconstrictor genes has been successfully used in animal models of both forms of hypertension. Furthermore, the use of viral vectors to deliver these constructs has achieved long-term control of hypertension. The successful establishment of gene therapy techniques in the animal models of hypertension coupled with the anticipated advances in the genetic aspects of this disease would make it highly feasible to attempt gene delivery in the control of human hypertension.
Gelband
C H
CH
Department of Physiology, College of Medicine, University of Florida, Gainesville, FL 32610-0274, USA. gelband@phys.med.ufl.edu
Katovich
M J
MJ
Raizada
M K
MK
D018674:Adrenergic Antagonists / Q000627:therapeutic use; D000818:Animals; D005544:Forecasting; D015316:Genetic Therapy; D006801:Humans; D006973:Hypertension / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D018342:Receptors, Adrenergic, beta-1 / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D012084:Renin-Angiotensin System; D014665:Vasodilator Agents / Q000378:metabolism
D018674:Adrenergic Antagonists; D016376:Oligonucleotides, Antisense; D018342:Receptors, Adrenergic, beta-1; D014665:Vasodilator Agents